{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T12:51:04Z","timestamp":1764679864804,"version":"3.46.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Intensiva (English Edition)"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.medine.2025.502268","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T05:51:50Z","timestamp":1758952310000},"page":"502268","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Linezolid continuous infusion protects from subtherapeutic linezolid concentrations in critically ill patients"],"prefix":"10.1016","volume":"49","author":[{"given":"Leonardo","family":"Lorente","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Gonz\u00e1lez Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"P\u00e9rez Reyes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristo Yared","family":"P\u00e9rez Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Rod\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"Viera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medine.2025.502268_bib0005","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s40360-022-00628-9","article-title":"Safety of linezolid in patients with decreased renal function and trough monitoring: a systematic review and meta-analysis","volume":"23","author":"Liu","year":"2022","journal-title":"BMC Pharmacol Toxicol."},{"key":"10.1016\/j.medine.2025.502268_bib0010","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/17512433.2023.2181160","article-title":"Hematological toxicities associated with linezolid therapy in adults: key findings and clinical considerations","volume":"16","author":"Cattaneo","year":"2023","journal-title":"Expert Rev Clin Pharmacol."},{"key":"10.1016\/j.medine.2025.502268_bib0015","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00228-022-03446-4","article-title":"Linezolid pharmacokinetics: a systematic review for the best clinical practice","volume":"79","author":"Heidari","year":"2023","journal-title":"Eur J Clin Pharmacol."},{"key":"10.1016\/j.medine.2025.502268_bib0020","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1093\/jac\/dkt133","article-title":"High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia","volume":"68","author":"Nukui","year":"2013","journal-title":"J Antimicrob Chemother."},{"key":"10.1016\/j.medine.2025.502268_bib0025","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2165\/11532080-000000000-00000","article-title":"Comparison of the pharmacokinetics of two dosage regimens of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patients","volume":"49","author":"Alffenaar","year":"2010","journal-title":"Clin Pharmacokinet."},{"key":"10.1016\/j.medine.2025.502268_bib0030","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/FTD.0b013e3181cc6d6f","article-title":"Limited sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis","volume":"32","author":"Alffenaar","year":"2010","journal-title":"Ther Drug Monit."},{"key":"10.1016\/j.medine.2025.502268_bib0035","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/jac\/dku337","article-title":"Pharmacokinetic\/pharmacodynamic evaluation of linezolid in hospitalized paediatric patients: a step toward dose optimization by means of therapeutic drug monitoring and Monte Carlo simulation","volume":"70","author":"Cojutti","year":"2015","journal-title":"J Antimicrob Chemother."},{"key":"10.1016\/j.medine.2025.502268_bib0040","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/FTD.0000000000000473","article-title":"Comparison of the ARK immunoassay with high-performance liquid chromatography with ultraviolet detection for therapeutic drug monitoring of linezolid","volume":"40","author":"Castoldi","year":"2018","journal-title":"Ther Drug Monit."},{"key":"10.1016\/j.medine.2025.502268_bib0045","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3109\/00365548.2011.608712","article-title":"Correlation between serum linezolid concentration and the development of thrombocytopenia","volume":"44","author":"Hiraki","year":"2012","journal-title":"Scand J Infect Dis."},{"key":"10.1016\/j.medine.2025.502268_bib0050","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ijantimicag.2014.05.010","article-title":"Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients","volume":"44","author":"Matsumoto","year":"2014","journal-title":"Int J Antimicrob Agents."},{"key":"10.1016\/j.medine.2025.502268_bib0055","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1093\/jac\/dks153","article-title":"Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients","volume":"67","author":"Pea","year":"2012","journal-title":"J Antimicrob Chemother."},{"key":"10.1016\/j.medine.2025.502268_bib0060","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s10156-010-0080-6","article-title":"Thrombocytopenia and anemia caused by a persistent high linezolid concentration in patients with renal dysfunction","volume":"17","author":"Tsuji","year":"2011","journal-title":"J Infect Chemother."},{"key":"10.1016\/j.medine.2025.502268_bib0065","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1128\/AAC.01453-12","article-title":"Pharmacokinetics of intravenous linezolid in moderately to morbidly obese adults","volume":"57","author":"Bhalodi","year":"2013","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.medine.2025.502268_bib0070","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1128\/AAC.01885-13","article-title":"Clinical population pharmacokinetics and toxicodynamics of linezolid","volume":"58","author":"Boak","year":"2014","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.medine.2025.502268_bib0075","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/jcph.296","article-title":"Target site pharmacokinetics of linezolid after single and multiple doses in diabetic patients with soft tissue infection","volume":"54","author":"Eslam","year":"2014","journal-title":"J Clin Pharmacol."},{"key":"10.1016\/j.medine.2025.502268_bib0080","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ijantimicag.2010.03.007","article-title":"Linezolid concentrations in infected soft tissue and bone following repetitive doses in diabetic patients with bacterial foot infections","volume":"36","author":"Traunm\u00fcller","year":"2010","journal-title":"Int J Antimicrob Agents."},{"key":"10.1016\/j.medine.2025.502268_bib0085","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1310309","article-title":"Towards a better detection of patients at-risk of linezolid toxicity in clinical practice: a prospective study in three Belgian hospital centers","volume":"15","author":"Thirot","year":"2024","journal-title":"Front Pharmacol."},{"key":"10.1016\/j.medine.2025.502268_bib0090","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40360-021-00479-w","article-title":"Proposal of initial and maintenance dosing regimens with linezolid for renal impairment patients","volume":"22","author":"Kawasuji","year":"2021","journal-title":"BMC Pharmacol Toxicol."},{"issue":"1 Pt 2","key":"10.1016\/j.medine.2025.502268_bib0095","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jfma.2020.06.011","article-title":"Impact of high plasma concentrations of linezolid in Taiwanese adult patients- therapeutic drug monitoring in improving adverse drug reactions","volume":"120","author":"Cheng","year":"2021","journal-title":"J Formos Med Assoc."},{"key":"10.1016\/j.medine.2025.502268_bib0100","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1128\/AAC.01694-12","article-title":"Risk factors for a low linezolid trough plasma concentration in acute infections","volume":"57","author":"Morata","year":"2013","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.medine.2025.502268_bib0105","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1093\/jac\/dkz374","article-title":"Proactive therapeutic drug monitoring (TDM) may be helpful in managing long-term treatment with linezolid safely: findings from a monocentric, prospective, open-label, interventional study","volume":"74","author":"Cojutti","year":"2019","journal-title":"J Antimicrob Chemother."},{"key":"10.1016\/j.medine.2025.502268_bib0110","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s40262-020-00964-1","article-title":"Supra-therapeutic linezolid trough concentrations in elderly patients: a call for action?","volume":"60","author":"Cattaneo","year":"2021","journal-title":"Clin Pharmacokinet."},{"key":"10.1016\/j.medine.2025.502268_bib0115","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/bcpt.12797","article-title":"A 10-year experience of therapeutic drug monitoring (TDM) of linezolid in a hospital-wide population of patients receiving conventional dosing: is there enough evidence for suggesting TDM in the majority of patients?","volume":"121","author":"Pea","year":"2017","journal-title":"Basic Clin Pharmacol Toxicol."},{"key":"10.1016\/j.medine.2025.502268_bib0120","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1186\/s12879-023-08831-7","article-title":"Linezolid dose adjustment according to therapeutic drug monitoring helps reach the goal concentration in severe patients, and the oldest seniors benefit more","volume":"23","author":"Xu","year":"2023","journal-title":"BMC Infect Dis."},{"key":"10.1016\/j.medine.2025.502268_bib0125","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.2147\/DDDT.S303497","article-title":"Pharmacokinetics of linezolid dose adjustment for creatinine clearance in critically ill patients: a multicenter, prospective, open-label, observational study","volume":"15","author":"Wang","year":"2021","journal-title":"Drug Des Devel Ther."},{"key":"10.1016\/j.medine.2025.502268_bib0130","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s10096-013-2041-3","article-title":"Therapeutic drug monitoring and receiver operating characteristic curve prediction may reduce the development of linezolid-associated thrombocytopenia in critically ill patients","volume":"33","author":"Dong","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis."},{"key":"10.1016\/j.medine.2025.502268_bib0135","doi-asserted-by":"crossref","first-page":"5254","DOI":"10.1128\/AAC.00356-16","article-title":"Predictors of inadequate linezolid concentrations after standard dosing in critically ill patients","volume":"60","author":"Taubert","year":"2016","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.medine.2025.502268_bib0140","doi-asserted-by":"crossref","first-page":"R148","DOI":"10.1186\/cc13984","article-title":"Variability of linezolid concentrations after standard dosing in critically ill patients: a prospective observational study","volume":"18","author":"Zoller","year":"2014","journal-title":"Crit Care."},{"key":"10.1016\/j.medine.2025.502268_bib0145","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1128\/AAC.00515-06","article-title":"Pharmacokinetics of intravenous linezolid in cerebrospinal fluid and plasma in neurointensive care patients with staphylococcal ventriculitis associated with external ventricular drains","volume":"51","author":"Beer","year":"2007","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.medine.2025.502268_bib0150","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ijantimicag.2014.07.001","article-title":"Plasma and cerebrospinal fluid concentrations of linezolid in neurosurgical critically ill patients with proven or suspected central nervous system infections","volume":"44","author":"Luque","year":"2014","journal-title":"Int J Antimicrob Agents."},{"key":"10.1016\/j.medine.2025.502268_bib0155","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1097\/FTD.0000000000000665","article-title":"Linezolid dosing in patients with liver cirrhosis: standard dosing risk toxicity","volume":"41","author":"Luque","year":"2019","journal-title":"Ther Drug Monit."},{"key":"10.1016\/j.medine.2025.502268_bib0160","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1128\/AAC.00051-06","article-title":"Serum and cerebrospinal fluid concentrations of linezolid in neurosurgical patients","volume":"50","author":"Myrianthefs","year":"2006","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.medine.2025.502268_bib0165","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00228-009-0766-9","article-title":"Pharmacokinetics of linezolid in septic patients with and without extended dialysis","volume":"66","author":"Swoboda","year":"2010","journal-title":"Eur J Clin Pharmacol."},{"key":"10.1016\/j.medine.2025.502268_bib0170","doi-asserted-by":"crossref","first-page":"e01619","DOI":"10.1128\/AAC.01619-20","article-title":"Evaluation of linezolid pharmacokinetics in critically ill obese patients with severe skin and soft tissue infections","volume":"65","author":"Blackman","year":"2021","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.medine.2025.502268_bib0175","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3390\/pharmaceutics12010054","article-title":"Novel population pharmacokinetic model for linezolid in critically ill patients and evaluation of the adequacy of the current dosing recommendation","volume":"12","author":"Soraluce","year":"2020","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.medine.2025.502268_bib0180","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ijid.2020.02.044","article-title":"Impact of augmented renal clearance on the pharmacokinetics of linezolid: advantages of continuous infusion from a pharmacokinetic\/pharmacodynamic perspective","volume":"93","author":"Barrasa","year":"2020","journal-title":"Int J Infect Dis."},{"key":"10.1016\/j.medine.2025.502268_bib0185","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00134-014-3550-y","article-title":"Linezolid plasma and intrapulmonary concentrations in critically ill obese patients with ventilator-associated pneumonia: intermittent vs continuous administration","volume":"41","author":"De Pascale","year":"2015","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.medine.2025.502268_bib0190","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ijantimicag.2007.09.009","article-title":"Linezolid pharmacokinetic\/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion","volume":"31","author":"Adembri","year":"2008","journal-title":"Int J Antimicrob Agents."},{"key":"10.1016\/j.medine.2025.502268_bib0195","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1007\/s00228-022-03340-z","article-title":"Applying pharmacokinetic\/pharmacodynamic measurements for linezolid in critically ill patients: optimizing efficacy and reducing resistance occurrence","volume":"78","author":"El-Gaml","year":"2022","journal-title":"Eur J Clin Pharmacol."},{"key":"10.1016\/j.medine.2025.502268_bib0200","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1097\/00003246-198510000-00009","article-title":"APACHE II: a severity of disease classification system","volume":"13","author":"Knaus","year":"1985","journal-title":"Crit Care Med."},{"key":"10.1016\/j.medine.2025.502268_bib0205","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron."},{"key":"10.1016\/j.medine.2025.502268_bib0210","series-title":"Applied Regression Analysis and Other Multivarible Methods","first-page":"281","article-title":"Polynomial regression","author":"Kleinbaum","year":"1998"}],"container-title":["Medicina Intensiva (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173572725001900?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173572725001900?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T12:47:49Z","timestamp":1764679669000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173572725001900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":42,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2173572725001900"],"URL":"https:\/\/doi.org\/10.1016\/j.medine.2025.502268","relation":{},"ISSN":["2173-5727"],"issn-type":[{"type":"print","value":"2173-5727"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Linezolid continuous infusion protects from subtherapeutic linezolid concentrations in critically ill patients","name":"articletitle","label":"Article Title"},{"value":"Medicina Intensiva (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medine.2025.502268","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Espa\u00f1a, S.L.U. and SEMICYUC. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"502268"}}